Stay updated on Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.

Latest updates to the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows an expanded list of study locations and updated contact details. The core study design, eligibility criteria, and outcome measures appear unchanged.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check41 days agoChange Detected- Updated notice about government funding lapse and current operating status with links to official sources. - Version bumped from v3.1.0 to v3.2.0.SummaryDifference3%

- Check49 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.1%

- Check63 days agoChange DetectedVersion updated to v3.0.2, replacing v3.0.1; the 'Back to Top' link was removed.SummaryDifference0.2%

- Check70 days agoChange DetectedThe web page has been updated from version v3.0.0 to v3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check77 days agoChange DetectedThe web page has undergone significant updates, including the addition of numerous facility locations across various countries, while also removing several previous location entries. Additionally, there are updates to the names of certain compounds and a revision number change.SummaryDifference7%

Stay in the know with updates to Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib Combo in Metastatic Pancreatic Adeno Clinical Trial page.